Company Overview of Cold Spring Harbor Laboratory Inc.
Cold Spring Harbor Laboratory Inc. (CSHL) is a research and educational institution. The company conducts research programs focusing on cancer, neurobiology, plant genetics, genomics, and bio-informatics. It also offers graduate and undergraduate courses in the fields of cancer biology, neuroscience, plant biology, cellular and molecular biology, genetics, macromolecular structure, and bioinformatics. The company is based in Cold Spring Harbor, New York.
1 Bungtown Road
Cold Spring Harbor, NY 11724
Founded in 1963
Key Executives for Cold Spring Harbor Laboratory Inc.
Chief Executive Officer, President and Trustee
Chairman of the Board of Trustees
Compensation as of Fiscal Year 2014.
Cold Spring Harbor Laboratory Inc. Key Developments
Cold Spring Harbor Laboratory Inc. Settles Lawsuit in Patent Malpractice Case
Jun 3 14
Cold Spring Harbor Laboratory Inc. reached a settlement with Boston-based law firm Ropes & Gray over a malpractice suit regarding patent-issuing rights. CSHL attorneys proceeded with the malpractice suit, allowing outside researchers to also use the technology as a biomedical tool in cancer research and drug development. The Hannon shRNA is lauded by CSHL researchers as a â considerable advance over other technologies that has had a significant impact on academic and medical research, including its use to recognize new drug targets and treatments for cancer.
Ohr Pharmaceutical and Cold Spring Harbor Laboratory Announce Joint Venture to Develop Trodusquemine and Related Analogs
Mar 3 14
Ohr Pharmaceutical, Inc. announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs. The new joint venture will be a private entity, initially with equal ownership by Ohr and Cold Spring Harbor Laboratory. The two partners will seek funding and contribute to the research and development of trodusquemine and also newly patented analogs. The goal is to take the program into the clinic and to demonstrate proof of concept. Various options to fund later stage clinical trials will be explored. The continued preclinical research will be conducted under the guidance of Dr. Nicholas Tonks at CSHL. The enzyme protein tyrosine phosphatase 1B (PTB1B) is a well-characterized target for a range of therapy areas. Despite its extensive validation, PTP1B has been a challenging target for therapeutic development due to the chemical properties of the enzyme at its active site. Novel approaches are required to exploit this important target fully. In one such approach, have identified Trodusquemine as a selective, allosteric inhibitor of PTP1B that exerts its effects outside the active site of the enzyme. Trodusquemine has also been shown to cross the blood brain barrier, which enhances its potential applications, and has been well tolerated in dose escalation and dose ranging clinical studies completed to date in over 65 patients. Analogs of Trodusquemine have been identified that are potent inhibitors of PTP1B and have potential delivery route advantages.
Cold Spring Harbor Laboratory Appoints Teri F. Willey as Vice President of Business Development and Technology Transfer
Sep 10 13
Spring Harbor Laboratory (CSHL) announced that Teri F. Willey has been appointed Vice President of Business Development and Technology Transfer. In this newly created position, Ms. Willey will direct the Laboratory's commercialization and technology transfer activities, including patenting, licensing, company start-ups, and corporate partnerships and collaborations. Ms Willey joins CSHL from Mount Sinai Medical Center, where she successfully led the center's technology transfer and business development efforts. John Maroney, who previously had responsibility for technology transfer activities, will continue in his role as General Counsel. Most recently, she served as Vice President of Technology & Business Development at Mount Sinai Medical Center in Manhattan.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|